Dr. Gordon on the Role of Checkpoint Inhibitors in Hematologic Malignancies

Video

Leo I. Gordon, MD, professor of medicine, Feinberg School of Medicine, Northwestern University, discusses the role of checkpoint inhibitors for patients with hematologic malignancies.

Leo I. Gordon, MD, professor of medicine, Feinberg School of Medicine, Northwestern University, discusses the role of checkpoint inhibitors for patients with hematologic malignancies.

According to Gordon, there was an international trial of 72 patients who received pidilizumab (CT-011), which is one of the first checkpoint inhibitors. It may not work as a checkpoint inhibitor, but there was very little toxicity associated with the drug.

The PLATFORM study is going to be combining the checkpoint inhibitor durvalumab (Imfinzi) with CAR T cells in patients with diffuse large B-cell lymphoma (DLBCL). It makes sense to combine the checkpoint inhibitors with CAR T cells; however, the safety issues, the dosing, and the sequencing still need to be determined, states Gordon.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD